West Pharmaceutical Services, Inc. $WST Stock Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lowered its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 4.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 399,467 shares of the medical instruments supplier’s stock after selling 17,842 shares during the quarter. William Blair Investment Management LLC owned approximately 0.57% of West Pharmaceutical Services worth $148,106,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Addison Advisors LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $28,000. Avalon Trust Co purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $28,000. Cornerstone Planning Group LLC lifted its position in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares in the last quarter. Fulcrum Asset Management LLP grew its stake in West Pharmaceutical Services by 259.4% in the 3rd quarter. Fulcrum Asset Management LLP now owns 115 shares of the medical instruments supplier’s stock valued at $43,000 after acquiring an additional 83 shares during the period. Finally, Elevation Wealth Partners LLC grew its stake in West Pharmaceutical Services by 1,377.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 133 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 124 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $416.34 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.10. The stock’s 50 day simple moving average is $380.32 and its 200-day simple moving average is $320.84. The company has a market cap of $29.00 billion, a PE ratio of 46.73, a price-to-earnings-growth ratio of 2.53 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $438.27.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The firm had revenue of $874.50 million during the quarter, compared to analysts’ expectations of $827.12 million. During the same period in the previous year, the business earned $1.96 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 9.45 EPS for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be paid a dividend of $0.26 per share. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.67%.

Analysts Set New Price Targets

WST has been the subject of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and set a $475.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, November 2nd. Evercore reiterated an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, November 2nd. Finally, Wall Street Zen upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $424.67.

Check Out Our Latest Research Report on WST

Insider Transactions at West Pharmaceutical Services

In other news, VP Annette Favorite sold 2,524 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the sale, the vice president owned 21,818 shares of the company’s stock, valued at $7,963,570. This represents a 10.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 15,659 shares of company stock worth $5,443,749. Insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

See Also

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.